StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
Shares of NASDAQ:AKTX opened at $2.32 on Friday. The firm has a 50 day moving average of $3.12 and a 200-day moving average of $2.73. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40.
Akari Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Akari Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Buy P&G Now, Before It Sets A New All-Time High
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.